Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Why Moderna Inc. (MRNA) is Skyrocketing? A scientist surrounded by vials and beakers in a modern laboratory, proudly displaying a vaccine. The latest guidance reduction was the second time in the ...

Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a ...

Moderna secures a multi-year agreement to supply its COVID-19 vaccine to 17 European countries, including Norway and North Macedonia. Vaccine formats include prefilled syringes, reducing ...

“We also observed a rapid, substantial, and durable expansion of new T cell clones related specifically to the vaccine.” Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early ...

Massachusetts-based Moderna will likely be the first to manufacture a bird flu vaccine, backed by hundreds of millions in government funding. The biopharmaceutical giant is developing the vaccine ...

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...

Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market ... justifying a "hold" position rather than a "sell.". Moderna (NASDAQ:MRNA), which went public at ...

MDV: Multidose vial; NA: Not available ... influenza vaccination campaign estimated that the total time to get a vaccine ready to be administered per patient was 87 s for MDVs and 49.71 s for ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the ...